A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Genentech
Dejan Juric
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Genentech
George R. Blumenschein
Consultant or Advisory Role - Genentech
Research Funding - Genentech
José Baselga
Consultant or Advisory Role - Genentech
Desamparados Roda Perez
No relevant relationships to disclose
Rodrigo Dienstmann
No relevant relationships to disclose
Antonio Calles
No relevant relationships to disclose
Antonio Jimeno
No relevant relationships to disclose
Sandra Sanabria
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Catherine Littman
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Lukas C. Amler
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Andrea Pirzkall
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Josep Tabernero
Consultant or Advisory Role - Genentech